Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.

Pharmacogenetics and genomics - 1 Jun 2017

Thiesen Signe, Yin Peng, Jorgensen Andrea L, Zhang Jieying Eunice, Manzo Valentina, McEvoy Laurence, Barton Christopher, Picton Susan, Bailey Simon, Brock Penelope, Vyas Harish, Walker David, Makin Guy, Bandi Srinivas, Pizer Barry, Hawcutt Daniel B, Pirmohamed Munir

Abstract excerpt

OBJECTIVES: Cisplatin ototoxicity affects 42-88% of treated children. Catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic variants have been associated with ototoxicity, but the findings have been contradictory. The aims of the study were as follows: (a) to investigate these associations in a carefully phenotyped cohort of UK children and (b) to perform a systematic review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acid Anhydride Hydrolases
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catechol O-Methyltransferase

Share to Cisplatin

Share to Hearing Loss

Share to Methyltransferases

Share to Odds Ratio

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 28445188
DOI: 10.1097/FPC.0000000000000281
PMCID: PMC5432027

Genes

COMT
ACYP2
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.PMID 28445188Read ↗

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.Semantic proximity Read ↗

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.Semantic proximity Read ↗

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.Semantic proximity Read ↗

Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.Semantic proximity Read ↗

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.Semantic proximity Read ↗

Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy.Semantic proximity Read ↗

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.Semantic proximity Read ↗

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Semantic proximity Read ↗

Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.Semantic proximity Read ↗

Genetic variants associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.Semantic proximity Read ↗

Challenges in interpreting the evidence for genetic predictors of ototoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.